Dong Yunyun, Bai Yujie, Liu Haitao, Yang Ziting, Chang Yunqing, Li Jianguang, Han Qixuan, Feng Xiufang, Fan Xiaole, Ren Xiaoqiang
School of Software, Taiyuan University of Technology, Taiyuan, Shanxi, China.
Information Management Department, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China.
Front Genet. 2024 Jun 14;15:1401544. doi: 10.3389/fgene.2024.1401544. eCollection 2024.
Synergistic medication, a crucial therapeutic strategy in cancer treatment, involves combining multiple drugs to enhance therapeutic effectiveness and mitigate side effects. Current research predominantly employs deep learning models for extracting features from cell line and cancer drug structure data. However, these methods often overlook the intricate nonlinear relationships within the data, neglecting the distribution characteristics and weighted probability densities of gene expression data in multi-dimensional space. It also fails to fully exploit the structural information of cancer drugs and the potential interactions between drug molecules. To overcome these challenges, we introduce an innovative end-to-end learning model specifically tailored for cancer drugs, named Dual Kernel Density and Positional Encoding (DKPE) for Graph Synergy Representation Network (DKPEGraphSYN). This model is engineered to refine the prediction of drug combination synergy effects in cancer. DKPE-GraphSYN utilizes Dual Kernel Density Estimation and Positional Encoding techniques to effectively capture the weighted probability density and spatial distribution information of gene expression, while exploring the interactions and potential relationships between cancer drug molecules via a graph neural network. Experimental results show that our prediction model achieves significant performance enhancements in forecasting drug synergy effects on a comprehensive cancer drug and cell line synergy dataset, achieving an AUPR of 0.969 and an AUC of 0.976. These results confirm our model's superior accuracy in predicting cancer drug combinations, providing a supportive method for clinical medication strategy in cancer.
协同用药是癌症治疗中的一项关键治疗策略,涉及联合使用多种药物以提高治疗效果并减轻副作用。当前的研究主要采用深度学习模型从细胞系和癌症药物结构数据中提取特征。然而,这些方法常常忽略数据中复杂的非线性关系,忽视多维空间中基因表达数据的分布特征和加权概率密度。它也未能充分利用癌症药物的结构信息以及药物分子之间的潜在相互作用。为了克服这些挑战,我们引入了一种专门为癌症药物量身定制的创新型端到端学习模型,即用于图协同表示网络的双核密度与位置编码(DKPE)(DKPEGraphSYN)。该模型旨在优化对癌症中药物联合协同效应的预测。DKPE-GraphSYN利用双核密度估计和位置编码技术有效捕捉基因表达的加权概率密度和空间分布信息,同时通过图神经网络探索癌症药物分子之间的相互作用和潜在关系。实验结果表明,我们的预测模型在一个综合的癌症药物和细胞系协同数据集上预测药物协同效应时实现了显著的性能提升,AUPR达到0.969,AUC达到0.976。这些结果证实了我们的模型在预测癌症药物组合方面具有卓越的准确性,为癌症临床用药策略提供了一种支持性方法。